Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H19NO5 |
Molecular Weight | 305.3258 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](C[C@@H](C)C(=O)N1[C@@H](CC2=C1C=CC=C2)C(O)=O)C(O)=O
InChI
InChIKey=QYGJWRUSSRDNLQ-BREBYQMCSA-N
InChI=1S/C16H19NO5/c1-9(7-10(2)15(19)20)14(18)17-12-6-4-3-5-11(12)8-13(17)16(21)22/h3-6,9-10,13H,7-8H2,1-2H3,(H,19,20)(H,21,22)/t9-,10-,13+/m1/s1
Molecular Formula | C16H19NO5 |
Molecular Weight | 305.3258 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Pentopril (CGS 13945) is a member of a series of l-glutarylindoline-2(S)-carboxylic acid derivatives. Pentopril was evaluated as an inhibitor of a cell-free preparation of angiotensin-converting enzyme (ACE) isolated from rabbit lung. Intravenous administration of incremental doses of pentopril to anesthetized normotensive rats produced a dose-related inhibition of angiotensin I (AI) pressor responses. The onset of inhibition of the A1 pressor response was rapid, and substantial inhibition occurred at 5 min after administration of the ACE inhibitors. Pentopril hydrolyzed in vivo to the biologically active free-acid form of CGS 13934. It was well tolerated in normal volunteers and hypertensive patients. Pentopril was developed for the treatment of both hypertension and congestive heart failure. Pentopril produced little clinical improvement and no biochemical improvement in a patients with rheumatoid arthritis.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Direct determination of angiotensin-converting enzyme inhibitors in plasma by radioenzymatic assay. | 1987 Apr |
|
Inhibition of renal clearance of furosemide by pentopril, an angiotensin-converting enzyme inhibitor. | 1987 May |
|
Pharmacokinetics of pentopril in the elderly. | 1987 Sep |
|
Effect of renal impairment on disposition of pentopril and its active metabolite. | 1988 Jul |
|
Pentopril-cimetidine interaction caused by a reduction in hepatic blood flow. | 1988 Mar |
|
A clinical and biochemical assessment of a nonthiol ACE inhibitor (pentopril; CGS-13945) in active rheumatoid arthritis. | 1990 May |
|
Biosensor for enantioselective analysis of S-cilazapril, S-trandolapril, and S-pentopril. | 1999 May |
|
Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. | 2002 |
|
On-line assay of the S-enantiomers of enalapril, ramipril and pentopril using a sequential injection analysis/amperometric biosensor system. | 2004 Nov 19 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3007583
Single doses - range 10-500 mg
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 21:50:35 GMT 2023
by
admin
on
Fri Dec 15 21:50:35 GMT 2023
|
Record UNII |
6F679R1PVJ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID501003020
Created by
admin on Fri Dec 15 21:50:35 GMT 2023 , Edited by admin on Fri Dec 15 21:50:35 GMT 2023
|
PRIMARY | |||
|
C041886
Created by
admin on Fri Dec 15 21:50:35 GMT 2023 , Edited by admin on Fri Dec 15 21:50:35 GMT 2023
|
PRIMARY | |||
|
13105688
Created by
admin on Fri Dec 15 21:50:35 GMT 2023 , Edited by admin on Fri Dec 15 21:50:35 GMT 2023
|
PRIMARY | |||
|
82950-75-2
Created by
admin on Fri Dec 15 21:50:35 GMT 2023 , Edited by admin on Fri Dec 15 21:50:35 GMT 2023
|
PRIMARY | |||
|
6F679R1PVJ
Created by
admin on Fri Dec 15 21:50:35 GMT 2023 , Edited by admin on Fri Dec 15 21:50:35 GMT 2023
|
PRIMARY |